LipiGesic™ M is Recognized by Headache Experts as an Excellent
First-Line Therapy for Acute Migraine Treatment
SCHOFIELD, Wis., Nov. 13, 2012 /PRNewswire/ -- PuraMed
BioScience®, Inc,. (OTCQB: PMBS) announces that its
homeopathic migraine formulation, LipiGesic® M, has been
recognized as an excellent first-line therapy in the
treatment of acute migraine. The declaration was made in the
online article "Advances in Drug Development for Acute
Migraine," [page 14] scheduled for publication in
an upcoming printed issue of Drugs, a medical journal
evaluating drugs and drug therapies read by over 500,000 healthcare
providers.
Authors Ryan J. Cady,
Candace L. Shade, and Roger K. Cady,
MD, reviewed 11 drugs, which are considered advancements in acute
migraine treatment. LipiGesic M was the only product described as
"an excellent first-line therapy for very early intervention, as
it is compatible with all other acute treatment options."
"With this 'excellent first-line therapy' designation,
consumers can be assured that headache experts have reviewed the
clinical study evidence for LipiGesic M's efficacy and have
determined that LipiGesic M is the first medication sufferers
should take to relieve migraine pain and migraine associated
symptoms," said Russell Mitchell,
president and CEO of PuraMed BioScience.
LipiGesic M is an over-the-counter, homeopathic formulation of
feverfew and ginger delivered in a sublingual (under-the-tongue)
gel for the acute treatment of migraine. Sublingual delivery
preserves the effectiveness of the active ingredients since they
are absorbed directly into the blood stream bypassing the digestive
system where breakdown occurs.
"Migraine sufferers are looking for relief, but many current
treatments produce severe and often debilitating side effects,"
said Mitchell. "Our non-drowsy formulation can relieve migraine
headaches without medication hangover symptoms at a fourth of the
cost of the top-selling prescription treatments. Inclusion in the
article as the only over-the-counter product in the advancement of
acute migraine treatment with the advantages of lower cost and
little to no risk of medication overuse or rebound headaches is
encouraging.
"This article and the results of the soon-to-be-completed
LipiGesic M children's study are significant milestones as we
continue to build awareness within both the medical and consumer
markets," said Mitchell.
Currently, LipiGesic M is available at both Walgreens and
CVS/pharmacy stores. One box of LipiGesic M typically treats four
headaches at a cost of approximately $5 per treatment.
About PuraMed BioScience®, Inc.:
PuraMed
BioScience, Inc. engages in the research, development, and
marketing of non-prescription medicinal and healthcare products.
PuraMed has completed a double blind placebo clinical trial for its
leading product, LipiGesic®M, a sublingual acute
treatment for the relief of migraine headaches, which was published
in the top-tier medical journal, Headache: The Journal of Head and
Face Pain.
LipiGesic®M has national distribution and is
available nationwide in some of the largest chain drug stores in
the United States. In addition to
LipiGesic® M, the Company also has plans to launch
LipiGesic® H for tension-type headaches as well as
LipiGesic® PM, which provides a remedy for insomnia and
other sleep disorders.
Forward-Looking Statements:
This news release
contains forward-looking statements regarding PuraMed BioScience,
Inc., and its future business plans, which statements involve known
and unknown risks and uncertainties. Such risks and uncertainties
may cause actual results and future achievements of PuraMed
BioScience to be materially different from those implied by these
forward-looking statements. PuraMed BioScience has and undertakes
no obligation to provide public updates and revisions to these
forward-looking statements to reflect any changes in its
expectations of future events.
Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and
CEO
715-359-6373
rmitchell@puramedbioscience.com
Product Website: www.lipigesic.com
Corporate Website: www.puramedbioscience.com
SOURCE PuraMed BioScience, Inc.